Health Canada approved Spartan Bioscience’s DNA analyzer, the Spartan Cube, as a rapid, accurate and portable COVID-19 test. Closely-held Spartan plans to immediately begin shipping the test to its federal and...
Bellerophon Therapeutics (NASDAQ:BLPH) submitted an IND to the FDA to study INOpulse, a pulsed nitric oxide (NO) system, for the treatment of patients with COVID-19. The IND follows the FDA’s allowance of treatment with...
iBio (NYSE AMERICAN:IBIO) signed two master services agreements (MSAs) and a memorandum of understanding (MoU) with the Infectious Disease Research Institute to support iBio’s SARS-CoV-2 virus-like particle vaccine...
Novavax (NASDAQ:NVAX) identified a coronavirus vaccine candidate, NVX-CoV2373, using its nanoparticle technology, and will initiate a first-in-human trial in mid-May. Novavax’s Matrix-M adjuvant will be incorporated...
Mesoblast (NASDAQ:MESO; ASX:MSB) received clearance from the FDA for an IND application to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 with intravenous infusions of its allogeneic...
IntelGenx Technologies (TSXV:IGX; OTCQX:IGXT) unveiled a series of initiatives aimed at helping the company address, and satisfactorily respond to, the complete response letter that it recently received from the FDA...
Profound Medical (NASDAQ:PROF; TSX:PRN) launched a newly designed TULSA Procedure website, for residents of the U.S. suffering from a prostate condition. “This new site aims to be credible and focused on providing clear...
Closely held Ennaid Therapeutics is advancing development of ENU200 as a therapeutic to treat the up to 80% of asymptomatic, mild-to-moderate cases of COVID-19 viral infections. ENU200 is a repurposed, patent-pending...
The FDA accepted for priority review Mesoblast’s (NASDAQ:MESO; ASX:MSB) biologics license application filing for RYONCIL, its allogeneic cell therapy for the treatment of children with steroid-refractory acute graft...
MEI Pharma’s (NASDAQ:MEIP) ME-401 received FDA fast track designation for the treatment of patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. The company is...